TIDMNCYT
RNS Number : 3606V
Novacyt S.A.
08 April 2019
NOVACYT EXPANDS DEVELOPMENT PARTNERSHIP
WITH IMMUNEXPRESS
Extension of contract continues multi-year assay
design and development program
Paris, France and Camberley, UK - 8 April 2019 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, today announces its molecular testing
division, Primerdesign Ltd. (Primerdesign), has expanded its assay
development contract with Immunexpress, Inc. (Immunexpress), a
U.S.-based molecular diagnostic company with the first FDA cleared
host response test for suspected sepsis patients, to further
support the development of rapid diagnostic assays for the
detection of sepsis.
Primerdesign has been working in partnership with Immunexpress
for over three years. This expansion reaffirms Immunexpress's
confidence in Primerdesign's development capabilities and
highlights the division's pivotal role in assay development as it
grows its relationships with leading diagnostics companies.
Sepsis is a potentially life-threatening complication in which a
person's immune system inappropriately responds to an infection by
triggering a broader inflammatory response, which could cause
damage to multiple organs and ultimately lead to death. Left
undiagnosed or untreated, a patient could die within a matter of
hours.
Early diagnosis of sepsis is a serious and challenging health
care issue, which the Centre for Disease Control (CDC) estimates
affects 1.7m people in the US per year and is responsible for
270,000 deaths. Annually, sepsis affects an estimated 27-30 million
people worldwide(2) and represents a major unmet medical need.
Sepsis is the most expensive condition treated in U.S. hospitals(3)
with a mean cost per severe sepsis patient of $US 24,638. Similar
mean hospital costs per patient for sepsis have been determined in
Europe ($US 37,424)(4) . In the U.S., between 2005 and 2014, the
total annual cost of sepsis hospitalization increased from $22.2B
to $38.1B(5) .
Rolland Carlson, PhD, CEO of Immunexpress, commented:
"Our continued partnership with Novacyt supports our joint
efforts to deliver multiplexed assays that improve the management
and clinical outcomes of sepsis patients around the world. We are
committed to developing diagnostic tests to enable clinicians to
manage patients with sepsis or suspected sepsis and we have been
impressed with Primerdesign's ability to rapidly develop assays and
their track record of CE marking diagnostic tests in a timely
manner."
Graham Mullis, Group CEO of Novacyt, added:
"I am delighted that we are entering into our sixth agreement
with Immunexpress to aid clinicians in patient management with
sepsis. This contract expansion adds further momentum to our
business-to-business segment and provides further validation of the
expertise our clinical assay development service offers.
"I am pleased with the team's progress converting a rich
pipeline of business-to-business opportunities into commercial
contracts. We aim to become the development partner of choice for
molecular diagnostic companies who wish to efficiently deliver
complex multiplexed assays."
Financial terms of the agreement have not been disclosed.
[1] https://www.cdc.gov/sepsis/datareports/index.html
2 World Sepsis Day Factsheet 2018, available at
https://www.worldsepsisday.org/sepsis. .
3 C. Paoli, et al. Epidemiology and Costs of Sepsis in the
United States - An Analysis Based on Timing of Diagnosis and
Severity Level, Critical Care Medicine 2018; 46: 1889-1897.
4 H. Arefian, et al., Hospital-related cost of sepsis: A
systematic review, Journal of Infection, 1-11 (2016).
5 M. Rubens, et al., Increasing Sepsis Rates in the United
States: Results From National Inpatient Sample, 2005 to 2014, J
Intensive Care Med, 885066618794136 (2018).
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
Stifel Nicolaus Europe Limited (Nominated Advisor and Joint
Broker)
Jonathan Senior / Fred Walsh / Ben Maddison
+44 (0)20 7610 7600
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com /
victoria.fostermitchell@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is a rapidly growing, international
diagnostics business generating an increasing portfolio of in vitro
and molecular diagnostic tests. Its core strengths lie in
diagnostics product development, commercialisation, contract design
and manufacturing. The Company's lead business units comprise of
Primerdesign and Lab21 Products, supplying an extensive range of
high quality assays and reagents worldwide. The Group directly
serves oncology, microbiology, haematology and serology markets as
do its global partners, which include major corporates.
For more information please refer to the website:
www.novacyt.com
About Immunexpress Inc.
Immunexpress is a Seattle-based molecular diagnostic company
committed to improving outcomes for patients suspected of sepsis.
Immunexpress' SeptiCyte(TM) technology rapidly quantifies, directly
from whole blood, specific molecular markers from the patient's own
immune system - the 'host response'. SeptiCyte(TM) LAB, recently
cleared by the FDA, is the first of its kind in using the host
immune system to differentiate systemic inflammatory response
syndrome (SIRS) and sepsis. Detecting the host's response to
infection has the potential to differentiate infection earlier,
faster and more accurately than finding the invading pathogen
because it is independent of whether or not the pathogen is present
in the sample. Immunexpress' pipeline includes several
sample-to-answer assays for near patient testing. For more
information visit http://www.immunexpress.com/.
Follow Immunexpress on Twitter and LinkedIn.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCCKODNCBKDFQK
(END) Dow Jones Newswires
April 08, 2019 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024